Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.60 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.60 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.60 |
| ▸ | DHODH | Q02127 | 4/20 | 0.59 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.56 |
| ▸ | PRMT5 | O14744 | 9/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17224929 | 0.91 | DHODH (0.71) | PARP1DHODHPRMT5 | |
| SCHEMBL17224985 | 0.85 | PARP1 (0.64) | PARP1DHODHCHEK2 | |
| SCHEMBL15985086 | 0.83 | PRMT5 (0.70) | DHODHCHEK2PRMT5 | |
| SCHEMBL19066900 | 0.83 | PDE5A (0.50) | PARP1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL15972177 | 0.81 | PRMT5 (0.67) | DHODHPRMT5 | |
| SCHEMBL15972401 | 0.81 | PRMT5 (0.67) | DHODHPRMT5 | |
| SCHEMBL15985084 | 0.79 | PRMT5 (0.74) | DHODHCHEK2PRMT5 | |
| SCHEMBL15972065 | 0.79 | PRMT5 (0.69) | DHODHPRMT5 | |
| SCHEMBL15985118 | 0.79 | PRMT5 (0.73) | DHODHCHEK2PRMT5 | |
| SCHEMBL30110749 | 0.78 | PRMT5 (0.61) | PARP1HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015166398-A1 | 3H-IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-11-05 | — | — | WO | claimed |
| WO-2022167402-A1 | METHODS OF THERAPY COMPRISING ADMINISTERING A THERAPEUTICALLY EFFECTIVE COMBINATION COMPRISING A DHODH INHIBITOR AND AN IDH INHIBITOR | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-08-11 | — | — | WO | disclosed |
| US-20210088520-A1 | TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE | SERVIER PHARMACEUTICALS LLC | 2021-03-25 | — | — | US | disclosed |
| US-20190025313-A1 | TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE | SERVIER PHARMACEUTICALS LLC | 2019-01-24 | — | — | US | disclosed |
| WO-2015166398-A1 | 3H-IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-11-05 | — | — | WO | disclosed |
| WO-2015166398-A1 | 3H-IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190025313-A1 | TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE | DHODH, IDH1, IDH3A | PARP1 3431/4885HDAC3 2220/4885HDAC4 1651/4885 |
| US-20210088520-A1 | TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE | DHODH, IDH1, IDH3A | PARP1 3431/4885HDAC3 2220/4885HDAC4 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.